

YURiA-PHARM IS A UKRAINIAN PHARMACEUTICAL GROUP WITH A GLOBAL OUTLOOK





GD-PHARM

CHEM@TEKA
CENTER OF PERSONALIZED MEDICINES

Diaco
BIOFARMACEUTICI

emTEKO





THE ONLY ONE OF THE TOP-5
UKRAINIAN PHARMACEUTICAL
COMPANIES BUILT FROM THE
GROUND UP

1990 FOUNDED

1998 YURiA-PHARM LTD. MANUFACTURING
ESTABLISHED IN CHERKASY





90%

OF THE PROFIT
REINVESTED



+20%

ANNUALY
TARGET GROWTH

KEY BUSINESS DIRECTIONS

R&D

Manufacturing

Marketing

Distribution

SCIENCE CENTER R&D LAB

- Adaptation, development and scaling of production technologies for biopharmaceutical APIs and medicines based on them
- Development of hyaluronic acid based products
- Development of active pharmaceutical ingredients (APIs)
- Development and implementation medicines for hospital and medical devices



THERAPEUTICS FOCUSES R&D

- Monoclonal antibodies
- Pulmonology
- Plasma expanders
- Oncology
- Anesthesia and Pain Medicine
- Regeneration medicines
- Neurology
- Nephrology
- Dermatology
- Anti-infective drugs
- Orphan diseases
- Cardio vascular diseases



600+ 20+

REGISTRATION
CERTIFICATES

NEW PRODUCTS
EVERY YEAR

INTENSIVE & RECOVERY



Strategic business unit (SBU) Intensive & Recovery is the largest revenue contributor, accounting for over 70% of the corporation's turnover. This strategic business unit is actively engaged in:

- developing world-class original product concepts aimed at solving current clinical challenges
- enhancing existing products with new clinical strategies and indications, including “Wave Breaker” and “Long Haul”

INFECTION & RESPIRATORY



The Anti-infection & Respiratory SBU is a dynamic business unit with the highest number of new launches. The INCURE association, which is part of this SBU, works on anti-TB drugs with the aim of addressing the major social issue that is severe tuberculosis.

PAINLESS & ONCOLOGY



Antipain & Oncology strategic business unit is focused on more than just development and introduction of innovative products – but also on creating comprehensive approaches revolving around the combination of products with unique services involving personalization, drug combination, service, and information.

MEDICAL DEVICES & NEPHROLOGY



The MD & Nephrology strategic business unit includes such key portfolios as:

- hyaluronic acid products, a portfolio with high international potential and quick scalability
- functional waters (ReO), a portfolio with a high growth dynamic and the option to expand existing distribution channels
- peritoneal dialysis products for renal failure patients



FUNCTIONAL WATER LINE

YURIA-PHARM IN UKRAINE

3,3%*

MARKET SHARE

№3

HOSPITAL DISTRIBUTOR IN
UKRAINE (7.8% MARKET SHARE)**

13,4%

MARKET SHARE IN PARENTERAL
MEDICINES *


№3

BY TURNOVER*

*Proxima, 2021, retail + hospital, published 02.22

** Proxima, Q1-Q4 2021, hospital, published 02.22


MARKET SHARE IN PARENTERAL DRUGS DOUBLED OVER THE PAST FIVE YEARS



OPERATIONS IN 49 COUNTRIES

25%

EXPORT SHARE



REGISTERED REPRESENTATIVE OFFICES



UZBEKISTAN



KAZAKHSTAN



MOLDOVA



KIRGHISIA



TAJIKISTAN



VIETNAM

PRODUCTION IN UKRAINE

290 mil

TOTAL PRODUCT UNITS / YEAR

204 mil

PHARMACEUTICAL PRODUCTS

86 mil

MEDICAL DEVICES

41

PRODUCTION LINES

25,000 m²

PRODUCTION AREA



PERSONALIZED PHARMACEUTICALS UKRAINE

XeM@TEKA

953

RECIPES

1076

ORDERS

143 914

PRIMARY PACKAGES

1800 m²

UNIQUE PRODUCTION
SPACE

93

EXTEMPORAL
PREPARATIONS



emTEKO

PRODUCTION IN ITALY (DIACO)

33 mil

PRODUCT UNITS / YEAR

7

PRODUCTION LINES

3 000 m²

PRODUCTION AREA

Diaco
BIOFARMACEUTICI

- 30. 000. 000
INFUSIA
- 2. 200. 000
COSMETIC
- 440. 000
MEDICAL DEVICE



NEW PRODUCTION SITE

2021 **25 000 m²**

LAUNCHING IN

- New design approaches are introduced at the facility engineering, which significantly increased productivity.
- The API synthesis site has been put into operation and licensed.
- Preparations for the launch of the section for the release of medicinal products in aseptic conditions are ongoing.



DISTRIBUTION



33 000 m²

COMBINED WAREHOUSE SPACE
IN UKRAINE

9200 m²

MTC MEDICAL CENTER
LTD. PHARMACY
WAREHOUSES

21202 m²

FINISHED PRODUCT
WAREHOUSES

2300 m²

YURiA-PHARM LTD.
PHARMACY WAREHOUSE



2800

EMPLOYEES



24.02.22

Since the beginning of the full-scale invasion, one of the priorities for YURiA-PHARM remains the continuity of activity, **because the output is vitally necessary in the conditions of war.**

PRODUCT CATEGORIES FOR WHICH DEMAND HAS SIGNIFICANTLY INCREASED:

- Parenteral nutrition
- Hemostatic
- Antimicrobial, antiseptics
- Anti-shock, blood substitutes
- Pain relievers
- Bandage materials, other medical products.

All production facilities in Ukraine are used for production, and all functions are working normally.



TOP 100

BECOME ONE OF THE TOP 100
PHARMACEUTICAL COMPANIES GLOBALLY
BY PURSUING THE COMPANY MISSION

«INTERNATIONAL PRODUCT»

PRODUCTS THAT ARE COMPETITIVE, IN
DEMAND, AND AVAILABLE OUTSIDE
UKRAINE

STRATEGY 2020-2030
